BioVie's bezisterim faces first Phase 2 test as monotherapy in untreated Parkinson's
SUNRISE-PD is the only trial testing an ERK1/2 and NF-κB inhibitor in Parkinson's, with topline data due after a five-month primary completion date slip.
Executive Summary
- BioVie has closed enrollment in a placebo-controlled Phase 2 trial testing whether its oral drug can improve motor symptoms in Parkinson's patients who have not yet started standard levodopa therapy, a use case distinct from its earlier combination study.
- The drug's anti-inflammatory mechanism has no other industry-sponsored trial testing it in Parkinson's disease, so the readout carries no comparator result to benchmark against, only the company's own prior combination data.
- The trial's primary completion date moved out five months as the study transitioned from recruiting to active-not-recruiting, a normal step at the end of enrollment rather than a sign of operational trouble.
- A positive result on motor symptoms without levodopa would extend bezisterim's rationale beyond the combination setting BioVie has already tested, while a null result would leave the anti-inflammatory hypothesis untested by any other sponsor in this indication.
The trial
SUNRISE-PD (NCT06757010) is a randomized, placebo-controlled Phase 2 study of bezisterim in patients diagnosed with idiopathic Parkinson's disease within 18 months who have not yet taken levodopa or a similar drug for motor symptoms. The trial enrolled 60 patients across four U.S. sites and moved from Recruiting to Active, not recruiting, on April 28, 2026. Its primary endpoint is change from baseline in the MDS-UPDRS Part III, the motor-symptom subscale of the standard Parkinson's rating instrument, with change in non-motor symptom scores and Clinical Global Impression improvement rate as secondary measures. NCT06757010A Study of NE3107 in Early Parkinson'sNCT06757010
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The mechanism and the prior signal
Bezisterim is an oral small molecule that crosses the blood-brain barrier and is designed to inhibit ERK- and NF-κB-driven inflammatory signaling without suppressing broader immune function, a pathway BioVie ties to insulin resistance and Parkinson's symptom progression. In an earlier completed Phase 2 study, patients with moderate to severe Parkinson's taking bezisterim alongside levodopa had better motor control and fewer reported morning symptoms than those on levodopa alone, with few drug-related side effects observed. SUNRISE-PD tests a different question: whether bezisterim alone, without levodopa, can move the same motor and non-motor measures in patients earlier in the disease course. BioVieBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment ...Apr 27, 2026
Timing: five-month completion shift
The trial's primary completion date moved from December 1, 2025, to May 1, 2026, the same registry update that recorded the status change to Active, not recruiting. That combination, a primary completion date pushed out alongside the shift away from active recruitment, is consistent with a trial reaching its enrollment target and needing more follow-up time to reach the primary analysis, not a sign of enrollment difficulty. Enrollment held flat at the original 60-patient target with no reduction, which an operational-risk read of enrollment changes classifies as a typical, non-flagged pattern for a trial of this design. A forecasting model puts the point estimate for the readout at July 26, 2026, with a 63% probability of landing within 180 days of that date. NCT06757010A Study of NE3107 in Early Parkinson'sNCT06757010
The competitive frame
No other industry-sponsored trial anywhere targets ERK1/2 in Parkinson's disease, and the closest ERK1/2-targeted trial in any indication, JS InnoPharm's JSI-1187 in tumors, tests a different disease and a different combination strategy. Within Parkinson's disease itself, the active field spans mechanistically distinct approaches: alpha-synuclein-targeted antibodies, GDNF gene therapy, and amyloid-precursor modulators, none of which share bezisterim's anti-inflammatory, insulin-sensitizing rationale. That leaves SUNRISE-PD without a same-mechanism precedent to benchmark against; the informative bar for this readout is whether a monotherapy effect on MDS-UPDRS Part III replicates the direction of benefit BioVie's earlier levodopa-combination study reported, since no other program has tested this pathway in this disease to compare against.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.